Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Positive Malignant Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00193089
What this trial is testing

Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer

Who this might be right for
Breast Cancer
SCRI Development Innovations, LLC 60
Testing effectiveness (Phase 2)Looking for participantsNCT06276868
What this trial is testing

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

Who this might be right for
Breast CancerHER2-positive Breast Cancer
Henan Cancer Hospital 71
Large-scale testing (Phase 3)Active Not RecruitingNCT05346224
What this trial is testing

Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmsHER2-positive Breast Cancer
Shanghai Henlius Biotech 900
Not applicableLooking for participantsNCT06603597
What this trial is testing

HER2-positive Breast Cancer Registry

Who this might be right for
HER2 + Breast Cancer
Priyanka Sharma 1,000
Testing effectiveness (Phase 2)Study completedNCT04752059
What this trial is testing

Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases

Who this might be right for
Breast Cancer Stage IV
Medical University of Vienna 15
Testing effectiveness (Phase 2)UnknownNCT05334810
What this trial is testing

DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer

Who this might be right for
HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 191
Large-scale testing (Phase 3)WithdrawnNCT05474690
What this trial is testing

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Who this might be right for
Breast CancerHER2-positive Breast Cancer
Henan Cancer Hospital
Testing effectiveness (Phase 2)Study completedNCT03112590
What this trial is testing

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

Who this might be right for
Breast CancerBreast Cancer, MaleBreast Cancer Female+1 more
H. Lee Moffitt Cancer Center and Research Institute 51
Early research (Phase 1)Ended earlyNCT05385705
What this trial is testing

Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

Who this might be right for
Breast Neoplasms
Vall d'Hebron Institute of Oncology 2
Not applicableLooking for participantsNCT06087120
What this trial is testing

Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment

Who this might be right for
Breast Cancer FemaleStage II Breast CancerStage III Breast Cancer+2 more
Gene Solutions 125
Not applicableUnknownNCT03947242
What this trial is testing

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.

Who this might be right for
HER2 Positive Breast Cancer
Henan Cancer Hospital 48
Testing effectiveness (Phase 2)Study completedNCT01783756
What this trial is testing

Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis

Who this might be right for
Central Nervous System MetastasesHER2-positive Breast CancerMale Breast Cancer+2 more
Jonsson Comprehensive Cancer Center 9
Large-scale testing (Phase 3)Study completedNCT00667251
What this trial is testing

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 652
Large-scale testing (Phase 3)Active Not RecruitingNCT04739761
What this trial is testing

T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 506
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07726342
What this trial is testing

SMP-656 for HER2-Positive Advanced Breast Cancer

Who this might be right for
HER2-positive Breast CancerMetastatic Breast CancerLocally Advanced Breast Cancer (LABC)
Chengdu SciMount Pharmatech Co., Ltd. 60
Testing effectiveness (Phase 2)Ended earlyNCT01363986
What this trial is testing

Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 3
Testing effectiveness (Phase 2)Study completedNCT03644186
What this trial is testing

To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)

Who this might be right for
Breast CancerEstrogen Receptor Positive TumorHER2-positive Breast Cancer
ETOP IBCSG Partners Foundation 147
Not applicableStudy completedNCT06021379
What this trial is testing

AryoTrust® (Trastuzumab) Safety Study

Who this might be right for
Breast Cancer
AryoGen Pharmed Co. 597
Not applicableLooking for participantsNCT07527741
What this trial is testing

Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment Decentralization

Who this might be right for
Early-stage HER2+ Breast Cancer
Hoffmann-La Roche 100
Not applicableLooking for participantsNCT06330012
What this trial is testing

The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.

Who this might be right for
HER2-positive Breast Cancer
Samsung Medical Center 50
Next Page